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The KRas/MAPK Pathway and Ligand Independent Activation of 
ERα: Implications for the Treatment of Endometrial Cancer 
Kari L. Ring, M.D. 
Thesis Advisor: Karen H. Lu, M.D. 
Hormonal therapy remains a first line option for the treatment of recurrent 
endometrial cancer (EC), however, many tumors demonstrate de novo or acquired 
resistance.  Member kinases of the PI3K/AKT and Ras/MAPK pathways activate 
estrogen receptor α (ERα) independent of estrogen, however, few studies have 
evaluated the role of the Ras/MAPK pathway in predicting response to hormonal 
therapy in EC.  The aims of this project were to evaluate the role of ligand 
independent activation of ERα in EC and to explore therapeutic implications for the 
treatment of recurrent EC. 
A xenograft model for recurrent EC was used to evaluate the effect of 
treatment with letrozole, everolimus, and metformin in vivo.  These studies 
demonstrated that tumors with an activating KRas mutation are resistant to 
treatment with letrozole even in combination with everolimus.  Tumor growth and 
cellular proliferation were reduced only after the addition of metformin. 
To assess signaling through ERα, cells with and without an activating KRas 
mutation were stimulated with estradiol and phosphorylation at serine 167 (ser167) 
and serine 118 (ser118) evaluated.  KRas mutant cells had decreased expression 
of ERα and this decrease in expression was mirrored in functional proteomic 
analysis.    KRas mutant cells had no detectable phosphorylation at ser167 and 
decreased phosphorylation at ser118 in response to estradiol stimulation, which 
was restored following treatment with a MEK inhibitor.  
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To address the functional consequence of differential estrogen signaling 
expression of estrogen induced genes and cell viability assays were evaluated.  
Following treatment with a MEK inhibitor, mutant KRas cells had increased 
expression of estrogen-induced genes compared to cells with wild type KRas, 
mirroring the increase in phosphorylation at ser167 and ser118. Treatment of 
mutant KRas cells with a MEK inhibitor in the presence of estradiol had no effect, 
while treatment with a MEK inhibitor in the absence of estradiol resulted in 
decreased cell viability. 
Endometrial cancer cells harboring KRas mutations are functionally ER 
negative and are resistant to treatment with hormonal therapy. The addition of 
hormonal therapy to MEK inhibition may provide added benefit for patients with 
recurrent endometrial cancer compared to either therapy alone, with an improved 
side effect profile.   
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1. Introduction 
1.1 Overview 
Endometrial cancer remains the most common gynecologic cancer in the 
United States with an estimated 52,630 new cases and 8,590 deaths in 2014(1).  
The majority of women who present with endometrial cancer are diagnosed with 
early stage disease and have a favorable overall survival of approximately 80-
90%(2).  Unfortunately, women who experience recurrence, specifically recurrence 
outside of the pelvis, have poor response to current therapies with an overall 
survival of 12 months(3).   
First line treatment for recurrent endometrial cancer includes hormonal 
therapy or cytotoxic therapy in the form of carboplatin and paclitaxel, however, the 
addition of targeted therapies based on tumor molecular profiles has recently been 
explored(4, 5).  The most common molecular pathways currently under investigation 
in the treatment of endometrial cancer include the Phosphatidylinositol 3-Kinase 
(PI3K)/Protein Kinase B (AKT) and Ras/mitogen-activated protein kinase (MAPK) 
pathways given the high rates of mutations in these pathways in endometrial 
cancer(6-13).    
 In addition, endometrioid endometrial adenocarcinoma is a hormonally driven 
cancer.  Unopposed estrogen exposure as a result of exogenous estrogen, such as 
post-menopausal hormone replacement therapy, or obesity is one of the most 
important risk factors for the development of this disease(2).  Indeed, while patients 
with low grade, hormone positive endometrial cancer have a favorable prognosis, 
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this patient population accounts for the majority of recurrences, given that 80% of 
endometrial cancers fit into this subtype(2).   
 There is a significant body of literature supporting the role of the PI3K/AKT 
pathway and the Ras/MAPK pathway in cancer in general and in the pathogenesis 
of endometrial cancer specifically.   As a result, there are numerous clinical trials 
currently open using inhibitors of these two pathways alone and in combination.  In 
addition, hormonal therapies alone and in combination with inhibitors of the 
PI3K/AKT pathway have been investigated in endometrial cancer.  However, no 
studies have addressed the interplay of all three pathways and the implications this 
interplay may have on the success of targeted therapy in the treatment of 
endometrial cancer. 
1.2 The PI3K/AKT Pathway 
The PI3K/AKT pathway plays a key role in cellular growth, metabolism, and 
survival(14). Endometrial cancer has the highest rate of molecular aberrations in the 
PI3K pathway compared to other cancer types and the PI3K/AKT pathway is the 
most commonly altered pathway in endometrial cancer(15, 16).   
There are 3 distinct classes of PI3Ks, which are categorized based on 
structure, substrate specificity, and lipid products.  Class IA PI3Ks are the most 
extensively studied class of PI3Ks and have been implicated in human cancer.  
Class IA PI3Ks exist as heterodimers made up of a p110 catalytic and p85 
regulatory subunit. The PI3K pathway can be activated by a variety of sources 
including ligand bound receptor tyrosine kinases (RTK), G protein-coupled 
receptors, and activated Ras(17). 
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In response to ligand binding, p85 binds to specific phosphotyrosine residues 
on activated RTKs and releases its inhibition of the p110 catalytic subunit.  This 
causes PI3K to localize to the plasma membrane where it is able to interact with its 
substrate, phosphatidylinositol 4,5-biphosphate (PIP2).  The p110 catalytic subunit 
can also be directly activated by G-protein coupled receptors and activated Ras(18, 
19).   
Activated PI3K phosphorylates PIP2, resulting in the conversion of PIP2 to 
phosphatidylinositol 3,4,5-triphosphate (PIP3).  This process is negatively regulated 
by the tumor suppressor phosphatase and tensin homolog (PTEN).  PIP3 binds the 
pleckstrin homology (PH) domain of phosphoinositide-dependent kinase 1 (PDK1) 
and AKT, both serine/threonine kinases, and positions the two proteins in close 
proximity(20).  This allows PDK1 to phosphorylate and activate AKT at threonine 
308(21, 22).  In addition, the mTOR-Rictor (rapamycin insensitive companion of 
mTOR) complex (mTORC2) phosphorylates AKT at serine 473(23).  
Phosphorylation at both threonine 308 and serine 473 is necessary for full activation 
of AKT.  Once activated, AKT acts as the central node of this pathway and controls 
multiple downstream cellular processes.   
One of the key downstream targets of AKT is the mammalian target of 
rapamycin (mTOR) complex.  Phosphorylated AKT inactivates the tuberous 
sclerosis 1/2 (TSC1/2) complex by inhibiting rheb GTPase activity and releases its 
inhibition on the mTOR-Raptor (mTOR-regulatory-associated protein) complex 
(mTORC1)(14).  This complex then phosphorylates eukaryotic initiation factor 4E-
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binding protein (4E-BP) and p70 ribosomal S6 kinase (p70S6K) which promotes 
protein synthesis and cellular proliferation (Figure 1). 
 
 
 
 
 
 
 
Molecular alterations can occur in multiple effectors in the PI3K/AKT 
pathway.  Activating somatic mutations can be found in the p85 regulatory unit 
(PIK3R1 and PIK3R2), the p110 catalytic subunit (PIK3CA), and in AKT(6-10).  In 
addition, both mutation and loss of expression of the tumor suppressor PTEN is 
seen in 34% and 80% of endometrioid endometrial tumors respectively, leading to 
uncontrolled activation of AKT (11-13).   
Figure 1.  Overview of the PI3K/AKT pathway. 
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1.3 The Ras/MAPK Pathway 
A second pathway known to play an important role in endometrial cancer is 
the Ras/MAPK pathway, which mediates cellular survival, proliferation, 
angiogenesis, and motility(24).  Like the PI3K/AKT pathway, the Ras/MAPK 
pathway can be activated by numerous sources including receptor tyrosine kinases, 
G protein-coupled receptors, cytokine receptors, and integrins(6, 24, 25). 
The Ras family of proteins, including the Kristen murine sarcoma viral 
oncogene homolog (KRas), NRas, and the Harvey rat sarcoma viral oncogene 
homolog (HRas) are small GTPases that reside in the cellular plasma membrane. 
Ras proteins cycle between the inactive guanosine diphosphate (GDP) bound and 
active guanosine triphosphate (GTP) bound conformation and act as the upstream 
switch for activation of downstream effectors in the MAPK pathway(26-28).  Docking 
sites for adaptor molecules and signal-relay proteins are created when ligands bind 
to receptor tyrosine kinases.  These activated receptor complexes contain adaptor 
proteins including SH2-containing protein (SHC), growth factor receptor bound 
protein 2 (GRB2), and GRB2-associated binding (Gab) protein.  This complex 
recruits SH2 domain-containing protein-tyrosine phosphatase (SHP2) and Son of 
Sevenless (SOS)1, which activate guanine nucleotide-exchange factors (GNEFs) 
and displace guanine nucleotides from Ras.  This process allows Ras to bind to 
GTP, resulting in activated Ras(28, 29). 
Activated Ras recruits the serine/threonine Raf family of kinases, including A-
Raf, B-Raf, and C-Raf to the plasma membrane.  Binding of Raf to Ras results in 
phosphorylation of Raf proteins which in turn phosphorylate and activate MEK1 and 
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MEK2 at multiple serine residues.  MEK1 and MEK2 are dual specificity 
serine/threonine and tyrosine kinases that activate and phosphorylate extracellular 
signal regulated-kinase (ERK)1 and ERK2 at both threonine and tyrosine residues.  
MEK1 and MEK2 have no known downstream effectors other than ERK1 and 
ERK2.  However, ERK1 and ERK2 have multiple downstream effectors, including 
p90RSK, which control a diverse number of cellular processes including cellular 
proliferation, apoptosis, and motility (Figure 2)(30-32). 
 
 
 
 
 
 
Oncogenic alterations in the Ras/MAPK pathway are found in endometrial 
cancer in the form of activating KRas mutations.  Mutant KRas is found in 10-30% 
Figure 2.  Overview of the Ras/MAPK pathway 
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of endometrioid endometrial cancers and frequently co-occurs with alterations in the 
PI3K/AKT pathway (6, 7, 33-37).   
1.4 Estrogen Receptor Alpha (ERα) 
It is well established that one of the key risk factors for the development of 
endometrial cancer is unopposed estrogen(38).  In addition, the majority of 
endometrioid endometrial cancers express ER, emphasizing the role for estrogen in 
the development and progression of endometrial cancer(39-41).  Estrogen signaling 
was once thought to be a relatively simple signal cascade.  Estrogen entered the 
cell and bound to ER in the cytoplasm, which dimerized and translocated to the 
nucleus, bound to estrogen response elements (EREs) in the promoters of ER 
responsive genes and modulated their transcription(42).  However, estrogen 
signaling has proved to be much more complex in recent years with estrogen now 
known to control both genomic and nongenomic signaling by ligand dependent and 
ligand independent mechanisms.  
Estrogen binds to two isoforms of ER in classical, genomic estrogen 
signaling: ERα and ERβ.  Of these, ERα plays a predominant role in the 
proliferation of both normal endometrium and endometrial cancer(43).    ERα is 
composed of several functional domains including the N-terminal domain, DNA 
binding domain (DBD), and C-terminal ligand-binding domain with a hormone-
dependent transcriptional activation function (AF-2).  The ligand-independent 
activation function (AF1) lies within the N-terminal domain and is the site of 
phosphorylation and activation of ERα(44).  ERα is phosphorylated and activated at 
several serine residues in AF1 including Serine 118 (Ser118) and Serine 167 
8 
 
(Ser167).  This activation can be accomplished both through ligand dependent and 
ligand independent phosphorylation (Figure 3). 
 
 
 
 
 
 
 
Ligand dependent phosphorylation, as a result of estrogen binding, occurs at 
Ser118(45). While there is debate regarding the specific kinase that is responsible 
for phosphorylation at Ser118 as a result of estrogen binding, one candidate is 
cyclin dependent kinase (Cdk)7(46).  Activation of ERα can also be accomplished 
through ligand independent phosphorylation at both Ser118 and Ser167 by several 
member kinases of receptor tyrosine kinase pathways, such as the PI3K/AKT and 
Ras/MAPK pathways, in the absence of estrogen.  ERK1/2 phosphorylates Ser118 
in the AF1 domain and is independent from the phosphorylation that occurs as a 
result of estrogen binding(45, 47-49).  In addition, AKT, p70S6K, and p90RSK have 
been found to phosphorylate and activate ERα at Ser167(50-55). 
Figure 3.  Serine phosphorylation sites on ERα at Ser118 
and Ser167  Ligand independent binding sites (A) and ligand 
dependent binding site (B). 
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Phosphorylation of serine residues in the AF1 domain of ERα mediates 
transcription of downstream genes through genomic signaling.  Here, 
phosphorylation of ERα leads to the formation of homo- or heterodimers and 
transport of the receptor to the nucleus.  Dimers bind to EREs which are located in 
promoter regions of target genes and help to form multi-protein complexes 
consisting of co-activators, co-repressors, histone acetyltransferases and histone 
deacetylases, leading to transcription of estrogen induced genes(56, 57).   
Nongenomic estrogen signaling results in rapid signaling through multiple 
protein kinase cascades and is thought to occur when estrogen binds to one of 
three membrane bound receptors: the G protein-coupled receptor (GPR30), the 
classic ERα, and a splice variant of ERα, ERα36(58-61).  Activation of these kinase 
cascades then lead to transcription of downstream target genes.  Estrogen bound 
GPR30 stimulates adenylate cyclase, ultimately leading to the release of 
membrane-tethered epidermal growth factor (EGF) and activation of the Ras/MAPK 
pathway via EGFR activation(59).  Membrane bound ERα trans-activates the EGF, 
Src, human epidermal growth factor 2 (ErbB2), and insulin growth factor (IGF)-1 
receptors, leading to downstream signaling in the Ras/MAPK and PI3K/AKT 
pathways(62-65).  In addition, ligand bound ERα has been shown to bind directly to 
the p85 regulatory subunit of PI3K, leading to activation of the PI3K/AKT 
pathway(66).  ERα36 is a 36-kDa isoform of ERα that lacks the AF1 and AF2 
domains, but retains the DBD, partial dimerization, and ligand binding domains.  
ERα36 also activates the PI3K/AKT and Ras/MAPK pathway in response to 
estrogen signaling(67, 68).  Figure 4 shows an overview of estrogen signaling. 
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1.5 Pathway Crosstalk 
 The PI3K/AKT, Ras/MAPK, and estrogen receptor pathways have multiple 
opportunities for crosstalk that must be considered when approaching the treatment 
of endometrial cancer.  As outlined above, both the PI3K/AKT and Ras/MAPK 
pathway are able to phosphorylate and activate ERα in the absence of estrogen.  In 
addition, both the Ras/MAPK and estrogen receptor pathways are able to 
crossactivate the PI3K/AKT pathway at multiple nodes(69).  Activated KRas is able 
to directly bind and activate the p110 catalytic subunit in the absence of ligand 
binding, leading to activation of AKT(18, 19).  ERK1/2 and p90RSK are able to 
Figure 4.  Overview of estrogen signaling 
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phosphorylate TSC2 at different sites than AKT, releasing its inhibition on mTORC1, 
ultimately leading to increased activation of mTORC1(70).  ERK 1/2 and p90RSK 
are also able to directly phosphorylate and activate mTORC1(71, 72).  In addition, 
estrogen binding to membrane bound ERα and ERα36 can lead to nongenomic 
activation of the PI3K/AKT pathway by direct binding of ERα to the p85 regulatory 
subunit of PI3K or through increased signaling through RTKs(62, 66).  Lastly, 
genomic estrogen signaling can lead to transcription of ligands  that activate 
receptor tyrosine kinases leading to activation of the PI3K/AKT pathway(65). 
 Similarly, both the PI3K/AKT and estrogen receptor pathways are able to 
crossactivate the Ras/MAPK pathway.  Conversion of PIP2 to PIP3 by PI3K recruits 
GAB to the plasma membrane.  Phosphorylated GAB interacts with numerous 
proteins including SHP2 and recruits the GRB2-SOS complex to the plasma 
membrane.  This interaction activates Ras and increases signaling though the 
MAPK pathway(73-76).  This interaction ultimately results in a PI3K/GAB/PI3K 
feedback loop that further increases PI3K/AKT signaling as well as signaling 
through the Ras-related C3 botulinium toxin substrate 1(Rac1)/cell division control 
protein 42 homolog (Cdc42)/p21 activated kinase (PAK) pathway.  PAK in turn 
phosphorylates Raf as well as MEK1(77-79).   
 Lastly, in addition to cross activation, there are multiple opportunities for 
crossinhibition between the PI3K/AKT and Ras/MAPK pathways(80, 81).  Release 
of this crossinhibition with single agent inhibition of one pathway could then lead to 
upregulation of compensatory pathways(81). 
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1.6 Targeted Therapies in the Treatment of Endometrial Cancer 
 There are multiple candidates for targeted therapeutics when considering the 
PI3K/AKT, Ras/MAPK, and ER pathways(5).  Unfortunately, thus far, single agent 
targeted therapies have produced disappointing results, reinforcing the need for 
combination therapies that target multiple relevant pathways in the treatment of 
endometrial cancer. 
A variety of inhibitors of PI3K, AKT and mTOR are currently available and 
many of these are currently being utilized in clinical trials.   The most extensively 
studied class of drugs in endometrial cancer includes rapalogs which act as 
mTORC1 inhibitors.   Everolimus (RAD001) is one of these rapalogs that also acts 
as a macrolide immunosuppressant.  A phase II single arm trial of everolimus in 
recurrent endometrial cancer resulted in an encouraging clinical benefit of 21% at 
16 weeks.  However, the best response seen in this trial was stable disease, with no 
complete or partial responses(82).  Two other mTOR inhibitors that have been 
evaluated in endometrial cancer specifically are temsirolimus (CC1-779) and 
ridaforolimus (AP23573).  Trials with these inhibitors, like everolimus, have shown 
impressive rates of stable disease ranging from 28-69%.  However, partial response 
was only seen in 4-14% of the populations studied, with no complete responses(83, 
84).   
Several therapeutic agents are currently available that target PI3K 
specifically or PI3K in combination with mTOR.  Investigation of predictive 
biomarkers for response to treatment with PI3K/AKT/mTOR inhibitors has centered 
on mutation of, or increased expression or activity of the members of the PI3K/AKT 
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pathway.  A retrospective review of patients enrolled in phase 1 trials with 
PI3K/AKT/mTOR inhibitors, including patients with endometrial cancer, showed that 
patients with PIK3CA mutations were more likely to respond with 35% partial 
response rate in a heavily pretreated group of patients(85).  On the other hand, both 
in vitro studies and clinical trials have found that KRas mutations may lead to 
resistance to PI3K/AKT/mTOR inhibition(85, 86).  
While KRas has proven difficult to target, MEK inhibitors are currently being 
investigated in phase I and II trials in various cancer types.  MEK inhibitors bind 
adjacent to the ATP binding site on MEK, leading to non-competitive interference 
with MEK function.  As a result, MEK inhibitors are highly specific.  This specificity is 
heightened as ERK is the only known downstream effector of MEK(87).  In 
preclinical studies, MEK inhibitors have been found to be cytostatic but not 
cytotoxic, supporting the notion that additional agents are needed in addition MEK 
inhibitors to affect tumor regression(88).  In addition, while BRAF mutant tumors are 
sensitive to MEK inhibition, tumors with activating KRas mutations have more 
variable responses(89, 90).  A single arm phase II trial of AZD6244, a MEK1/2 
inhibitor was performed by the GOG in patients with advanced or recurrent 
endometrial cancer.  The objective response rate was only 6% with 1 complete and 
2 partial responders, however 13 patients had stable disease(91).    The authors 
concluded that AZD6244 was tolerable, but did not meet pretrial specifications for 
clinical efficacy. 
 Previous work in our lab elucidated a novel mechanism of action of the oral 
hypoglycemic agent metformin in the treatment of KRas mutant endometrial 
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cancers.  Endometrial cancer cells with KRas mutations were more sensitive to 
treatment with metformin compared to cells with wild type KRas and this differential 
response was due to mislocalization of constitutively active KRas from the plasma 
membrane(92).  These preclinical findings support the use of metformin in KRas 
mutant endometrial cancers in combination with PI3K/AKT/mTOR inhibition. 
Lastly, multiple hormonal therapies have been evaluated in the treatment of 
recurrent endometrial cancer including progestins, tamoxifen, and aromatase 
inhibitors with response rates ranging from 10-30%(93-96).  Single agent letrozole, 
an aromatase inhibitor, showed disappointing results with a response rate of only 
9.4% in this patient population.  Given the extensive crosstalk between the 
PI3K/AKT, Ras/MAPK, and estrogen receptor pathways, the addition of 
PI3K/AKT/mTOR inhibitors and MEK inhibitors/metformin to hormonal therapies 
presents an opportunity for improved response in this patient population. 
1.7 Combination Therapy in Breast Cancer 
 Seventy percent of breast cancers are hormone receptor positive and 
endocrine therapy remains an integral part of the treatment for these patients(97, 
98).  However, despite having hormone positive disease, many tumors have de 
novo or acquired resistance to hormonal therapies(65).  Approximately 17- 30% of 
hormone positive breast cancer patients treated with endocrine therapy experience 
recurrence(99, 100).  This resistance is thought in part to be a result of crosstalk 
between the PI3K/AKT and ER pathway. As a result, much of the preclinical and 
clinical investigation to define ligand independent and nongenomic estrogen 
signaling has been performed in breast cancer.    
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Multiple clinical trials have been completed in breast cancer utilizing 
inhibitors of the PI3K/AKT pathway with endocrine therapy.  These trials have been 
performed in the neoadjuvant and recurrent setting with positive results(101).   One 
of these practice changing studies was The Breast Cancer Trials of Oral 
Everolimus-2 (BOLERO-2) trial.  This phase III randomized trial evaluated 
exemestane, an aromatase inhibitor, and everolimus or exemestane and placebo in 
hormone positive breast cancer refractory to nonsteroidal aromatase inhibitors.  
Patients treated with combination therapy had improved progression free survival 
compared to patients treated with exemestane plus placebo(102).  Exemestane and 
everolimus are now part of the NCCN guidelines for the treatment of patients with 
hormone refractory recurrent disease(103). 
1.8 Combination Therapy in Endometrial Cancer 
 Breast cancer and endometrial cancer share common molecular aberrations 
including positive hormone receptor expression and alterations in the PI3K/AKT 
pathway.  Given the success of dual inhibition of the PI3K/AKT and endocrine 
therapy in breast cancer, a phase II single arm trial of everolimus and letrozole was 
completed in patients with advanced or recurrent endometrial cancer.  Preliminary 
analysis of 35 evaluable patients revealed a 31% objective response rate with 8 
complete responses and 3 partial responses with median response duration of 12.6 
months.  An additional 6 patients had stable disease with a clinical benefit rate of 
49%(104).  These positive results contrast the previous single agent phase II trial of 
everolimus, where there we no objective responses and 6 patients with stable 
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disease for a clinical benefit rate of 21%(82).  Current studies are ongoing to identify 
predictive biomarkers for response to this treatment regimen. 
 Activating KRas mutations occur more frequently in endometrial cancer when 
compared to breast cancer(5, 105, 106). In addition, PTEN, PIK3CA, and PIK3R1 
mutations co-occur with KRas mutations in endometrial cancer, while these 
mutations are mutually exclusive in breast cancer(6, 7, 37, 106, 107).   
Differential responses to combination therapy with PI3K/AKT/mTOR 
inhibitors and endocrine therapy based on KRas mutation status may have 
important implications in the treatment of endometrial cancer.  Characterization of 
these responses could lead to novel combinations of targeted therapeutics based 
on tumor molecular profiles in the treatment of endometrial cancer.   
 Our first aim was to evaluate the addition of metformin to everolimus 
and letrozole, based on KRas mutation status in preclinical studies.  We 
hypothesized that tumors with an activating KRas mutation will be less responsive 
to everolimus and letrozole compared to tumors with wild-type KRas.  We also 
hypothesized that the addition of metformin to everolimus and letrozole will improve 
response in KRas mutant tumors.   Our second aim was to evaluate the role of 
nongenomic and ligand independent activation of ERα in preclinical studies of 
endometrial cancer.  We hypothesized that tumors with an activating KRas mutation 
have decreased activation of ERα and decreased dependence on the estrogen 
receptor signaling pathway. 
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2. Methods 
2.1 Cell Culture 
 Ishikawa, a well differentiated human endometrial carcinoma cell line with 
loss of PTEN expression, wild type KRas, and positive ERα expression, was 
purchased from the European Collection of Cell Cultures (EACC, Porton Down, 
United Kingdom).  Ishikawa cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 Medium with L-glutamine supplemented with 10% fetal bovine serum 
(FBS), penicillin (10,000 U/mL), and streptomycin (10,000 U/mL) (Table 1).  
Ishikawa cells had previously been transfected with a pMEV-2HA plasmid vector to 
stably express wild type KRas or mutant KRas (G12V) in our lab by David Iglesias.  
For the purposes of our in vitro studies, these cells were cultured in phenol free 
Dulbecco’s Modified Eagle Medium (DMEM) with L-glutamine and supplemented 
with 10% charcoal stripped FBS, penicillin (10,000 U/mL), and streptomycin (10,000 
U/mL).  HEC1A, a moderately differentiated human endometrial carcinoma cell line 
with intact PTEN expression, an activating KRas (G12D) mutation, and positive 
ERα expression was purchased from the American Type Culture Collection (ATCC, 
Manassas, VA) (Table 1).  Although these cells express ERα, they demonstrate 
limited response to exogenous estrogen.  HEC1A cells were cultured in RPMI 1640 
Medium with L-glutamine and supplemented with 10% FBS, penicillin (10,000 
U/mL), and streptomycin (10,000 U/mL).   
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Cell Line Cell Line Origin PI3K/AKT 
Status 
Ras/MAPK 
Status 
Hormone Receptor 
Status 
Ishikawa Grade 1 Endometrial 
Adenocarcinoma 
Loss of PTEN 
Expression 
KRas WT ERα +, ERβ +, PRα +, PRβ 
+ 
HEC1A Grade 2 Endometrial 
Adenocarcinoma 
PTEN WT KRas Mutation 
(G12D) 
ERα +, ERβ +, PRα +, PRβ 
+ 
 
 
 
2.2 Reagents and Inhibitors 
 Everolimus (RAD001), an mTORC1 inhibitor, was provided by the stand up 
to cancer (SU2C) foundation and was dissolved in sterile dimethyl sulfoxide 
(DMSO). Metformin (1,1-Dimethylbiguanide hydrochloride), letrozole (a non-
steroidal aromatase inhibitor), and β-estradiol were purchased from Sigma (St. 
Louis, MO) and dissolved in phosphate buffered saline (PBS), DMSO, and ethanol  
respectively.  Trametinib (GSK1120212) was graciously provided by the lab of Dr. 
Kwong K. Wong at the University of Texas MD Anderson Cancer Center and was 
dissolved in DMSO.  BEZ235, a dual pan-PI3K and mTOR inhibitor, was purchased 
from Selleck Chemicals (Houston, TX) and dissolved in DMSO. 
2.3 In Vivo Xenograft Study 
 We evaluated the addition of metformin to everolimus and letrozole based on 
KRas mutation status in an orthotopic model of recurrent endometrial cancer.   One 
hundred and sixty female athymic nude mice were purchased from the Department 
of Experimental Radiation Oncology at the University of Texas MD Anderson 
Cancer Center (Houston, TX).  Mice were housed with 5 animals per cage and were 
maintained in accordance with the Institutional Animal and Use Committee 
   Table 1. Known molecular aberrations in Ishikawa and HEC1A 
endometrial cancer cell lines 
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guidelines.  At 6 weeks of age, all mice underwent bilateral oophorectomy.  Mice 
were then allowed to recover for 7 days prior to intraperitoneal injection with 
endometrial cancer cells.   
Following recovery, each mouse was injected intraperitoneally with 5x106 
early-passage endometrial cancer cells (80 injected with Ishikawa cells, 80 injected 
with HEC1A cells).  Tumors were allowed to progress for 10 days and each group of 
80 mice were then placed into 1 of 8 treatment groups, with 10 mice in each 
treatment group.  The treatment groups included, control sesame oil gavage, 
metformin alone (2.5mg/kg/day), letrozole alone (0.275mg/kg/day), everolimus 
alone (5mg/kg/day), metformin and letrozole, metformin and everolimus, everolimus 
and letrozole, and all 3 drugs in combination.  Mice were treated by oral gavage of 
the assigned treatment suspended in 100uL of sesame oil (Figure 4).   
 
 
 
 
 
 
Figure 5.  Overview of xenograft model of recurrent 
endometrial cancer  
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Mice were treated daily until mice in any one treatment group became 
moribund at which time all mice in that experiment were euthanized.  Mice were 
weighed prior to necropsy and serum was collected and stored at -80°C.  All visible 
peritoneal tumor was dissected from the abdominal cavity, a portion placed in 
formalin, and embedded in paraffin.  The remainder was flash frozen and stored at -
80°C.   Serum was analyzed for alanine aminotransferase (ALT) level and along 
with mouse weight was used as a marker of treatment toxicity.   
2.4 Immunohistochemical Analysis of Xenograft Tissues 
 To evaluate treatment effect on downstream signaling through the PI3K/AKT 
pathway and cellular proliferation, immunohistochemistry (IHC) was performed on 
xenograft specimens.  Slides were cut from formalin-fixed, paraffin-embedded 
tissue and IHC for phosphorylated S6 ribosomal protein (pS6rp) and Ki-67 
expression were performed.  IHC staining was performed using the Lab VisionTM 
Autostainer 360-2D (Thermo Fisher Scientific, Waltham, MA) utilizing the Division of 
Surgery IHC Core at the University of Texas MD Anderson Cancer Center 
(Houston, TX).  Primary antibodies utilized were phosphorylated S6 ribosomal 
protein (S235/236) rabbit monoclonal antibody (Cell Signaling Technology, Beverly, 
MA) at 1:50 dilution and purified mouse anti-human Ki67 monoclonal antibody (BD 
Biosciences, San Diego, CA) at 1:50 dilution. 
 Slides were then scored in triplicate for both pS6rp and Ki-67.  
Phosphorylated S6rp was scored using a semi-quantitative system of intensity of 
staining (weak = 1, moderate = 2, strong = 3) and proportion of cells staining 
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positive (<10%= 0, 10-25% = 1, 26-50% = 2, 51-75% = 3, >75% = 4).  Ki-67 was 
scored as the proportion of nuclei staining positive compared to total nuclei in a 
high-powered field. 
2.5 Western Blot Analysis of ERα Signaling 
 To evaluate the differential response of Ishikawa and HEC1A tumors to 
treatment with letrozole, analysis of ERα signaling was performed using western 
blot.  Ishikawa cells stably transfected with wild type KRas and mutant KRas (G12V) 
were plated in 6 well plates to 70% confluency at 37°C under 5% CO2.  Cells were 
serum starved overnight for 12 hours in phenol free DMEM with L-glutamine 
containing DMSO alone, 10nM trametinib, or 10nM trametinib and 250nM BEZ235.   
While initial in vivo studies included everolimus and metformin, specific inhibitors of 
PI3K and MEK were utilized for in vitro studies to isolate effects on these pathways, 
given that both everolimus and metformin can act through inhibition of both the 
PI3K/AKT and Ras/MAPK pathway.  Cells were stimulated with 0.01uM estradiol 
and whole cell lysates were harvested at 0 minutes, 10 minutes, 30 minutes, 1 hour, 
and 4 hours.   Cells were washed thrice with sterile PBS.  Following this, 100uL of 
urea lysis buffer (3.1mL 1M Tris Hcl, pH6.8, 5mL 20% SDS, 5mL 100% glycerol, 
2.5mL 2-mercaptoethanol, 21g urea, bromophnol blue) was added to the culture 
plate.  Cells were harvested with a spatula and placed in 1.5mL centrifuge tubes.  
Proteins were denatured at 95°C for 5 minutes and cooled on ice.  Tubes were then 
centrifuged at 14,000 rpm for 5 minutes. 
 Equal amounts of protein (10uL) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel at 30mAmps.  
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Protein was transferred to an Immobilon polyvinylidene fluoride (PVDF) membrane 
(Millipore, Billerica, MA) over 30 minutes using 25V.  Membranes were blocked in 
5% nonfat dry milk for 1 hour and washed thrice in non-sterile 1X TBS with 500uL 
Tween-20 (1xTBST) for 5 minutes each.  Membranes were then incubated 
overnight with the primary antibody at 1:1000-1:2000 dilution in 5% bovine serum 
albumin (BSA) in TBST with gentle shaking at 4°C. Primary antibodies included 
phospho-estrogen receptor α (Ser167) (D1A3) Rabbit mAb, phosphor-estrogen 
receptor α (Ser118) (16J4) Mouse mAb, estrogen receptor α (D8H8) Rabbit mAb, 
phospho-AKT (Ser473) (D9E) XP Rabbit mAb, AKT Rabbit mAb, phospho p70 S6 
Kinase (Thr 389) Rabbit mAb, phospho-p44/42 MAPK (ERK1/2) Rabbit mAb, 
p44/42 MAPK (ERK1/2) Rabbit mAb, and phospho-p90RSK (Ser 380) Rabbit mAb.   
All primary and secondary antibodies, excluding β-actin, were purchased from Cell 
Signaling (Beverly, MA).  β-actin levels in each sample were used as a loading 
control.  Blots were stripped and reprobed using anti- β-actin mouse mAb (Sigma, 
St. Louis, MO ).   
 After overnight incubation in primary antibody, membranes were washed 
thrice in 1X TBST for 5 minutes each.  Membranes were then incubated in 5% 
nonfat milk in TBST containing the appropriate secondary anti-rabbit or anti-mouse 
IgG antibody at a 1:2000 dilution (Cell Signaling, Beverly, MA) for 1 hour.  
Membranes were again washed thrice in 1X TBST for 5 minutes each.  Antibody 
binding was then enhanced using Amersham ECL Prime Western Blotting Detection 
Reagent (GE Healthcare Life Sciences, Pittsburgh, PA) and developed. 
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 Relative densities were calculated for each protein of interest using Image J 
image processing program (National Institutes of Health, Bethesda, Maryland).  
These were normalized to β-actin controls for graphical depiction of western blot 
results.   
2.6 Quantitative Real Time PCR for Estrogen Induced Genes 
 To evaluate the downstream effect of differential signaling through ERα in 
KRas mutant cells, quantitative real time polymerase chain reaction (qRT-PCR) was 
performed with the aide of the Quantitative Genomics and Microarray Facilities Core 
at the University of Texas Medical School at Houston(108).  Ishikawa cells stably 
transfected with wild type KRas and mutant KRas (G12V) were plated in 6 well 
plates to 70% confluency at 37°C under 5% CO2.  Cells were serum starved 
overnight for 12 hours in phenol free DMEM with L-glutamine containing DMSO 
alone, 10nM trametinib, or 10nM trametinib and 250nM BEZ235.  Cells were then 
stimulated with 0.01uM estradiol and whole cell lysates were harvested at 16 hours.  
Total RNA was extracted from cell lysates using the RNeasy Mini Kit according to 
the manufacturer protocol (Qiagen, Valencia, CA) and DNAase treated RNA was 
diluted to 20ng/uL.  
Specific quantitative assays for estrogen-induced gene 121 (EIG121), 
secreted frizzled-related protein 1 (sFRP1), insulin-like growth factor 1(IGF-1), 
progesterone receptor (PR), homeobox A10 (HOXA10), ERα, and retinaldehyde 
dehydrogenase 2 (RALDH2) were developed using Beacon Designer, AlleleID 
(Premier Biosoft), or RealTimeDesign (Biosearch Technologies) based on the 
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refseq sequences from the NCBI. Real-time qPCR assay information is provided in 
Table 2. 
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Assay 
No. 
Species Accession No. Transcript Primes and Probes 
1 Mammal NR_003286 18SrRNA#2 1335 (+) CGGCTTAATTTGACTCAACAC 
1401 (-) ATCAATCTGTCAATCCTGTCC 
1359 (+) FAM-AAACCTCACCCGGCCCG-BHQ1 
Assay Efficiency = 1.939 
Amplicon Length = 68 
2 Hum NM_000675 KIAA1324 
(EIG121) 
2077 (+) CAACAAGATCCACTCTCTGTG 
2136 (-) AAAGCGGAGAAGTTGTAGTTG 
2110 (+) FAM-CACCTTCTCACGCAACACTCCGAC-
BHQ1  
Lowest quantifiable level = 230 
Assay efficiency = 1.983 
Amplicon Length = 89 
3 Hum NM_003012 hsFRP1 720(+)GAGCCGGTCATGCAGTTCT       
786(−)CCTCCGGGAACTTGTCACA        
740(+)FAM-CGGCTTCTACTGGCCCGAGATCG-
BHQ1   
Lowest quantifiable level = 230 
Assay efficiency = 2.021 
Amplicon Length = 67 
4 Hum NM_001111283 IGF1#2 217(+) CCTGGAGAACTGCACGGTGATCGA 
308 (-) GAGGAGGACATGGTGTGCA 
289(-) FAM-TCTTCACCTTCAAGAAATCACAAA-BHQ1 
Lowest quantifiable level = 230 
Assay efficiency = 1.979 
Amplicon Length = 92 
5 Hum NM_000926 PRgen#2 3400 (+) GAGCACTGGATGCTGTTGCT 
3465 (-) GGCTTAGGGCTTGGCTTTC 
3421 (+) FAM-TCCCACAGCCAGTTGGGCGTTC-
BHQ1       
Lowest quantifiable level = 230 
Assay efficiency = 1.996 
Amplicon Length = 66 
6 Hum NM_018951 HOXA10#2 1679 (+) CTGAGGTCAATGGTGCAAAG 
1758 (-) CCTGTATCCCCTGATTAAACAC 
1736 (-) FAM-AGCACAGCACTCCAGGCAGACA-
BHQ1 
Lowest quantifiable level = 230 
Assay efficiency = 2.033 
Amplicon Length = 81 
7 Hum NM_000125 ER-alpha#2 1394 (+)  TACTGACCAACCTGGCAGACAG 
1490 (-)  TGGACCTGATCATGGAGGGT 
1466 (-) FAM-TCCACAAAGCCTGGCACCCTCTTC-
BHQ1 
Lowest quantifiable level = 230 
Assay efficiency = 1.977 
Amplicon Length = 97 
8 Hum NM_003888 hRALDH2 2002(+)AGGCCCTCCTCGCTCAC        
2071(−)TCTGCCCCAGAATGAGCTC       
2021(+)FAM-ACCCCTCCCTCTCTTCCAAGGAGATC-
BHQ1       
Lowest quantifiable level = 230 
Assay efficiency = 1.972 
Amplicon Length = 86 
 
 
Table 2.  PCR primers and probes used in qRT-PCR 
26 
 
cDNA was synthesized in 5 µl (384-well plate) total volume by the addition of 
3 µl/well RT master mix consisting of: 400 nM assay-specific reverse primer, 500 
μM deoxynucleotides, Superscript II (or Affinityscript) buffer and 1 U/µl Superscript 
II (or Affinityscript) reverse transcriptase (Invitrogen, Carlsbad, CA), to a 384-well 
plate (Roche, Nutley, NJ) and followed by a 2 µl volume of sample (25-50 ng/µl). 
For 96-well plates, 6 µl RT master mix was added to each well followed by 4 µl of 
RNA sample (25 ng/µl). Each sample was assayed in triplicate plus a control 
without reverse transcriptase to access DNA contamination levels. Each plate also 
contained an assay-specific sDNA (synthetic amplicon oligo) standard spanning a 
5-log template concentration range and a no template PCR control. Both were 
added into RT master mix with reverse transcriptase. Each plate was covered with 
Biofilm A (Bio-Rad, Hercules, CA) and incubated in a PTC-100 (96) or DYAD (384) 
thermocycler (Bio-Rad, Hercules, CA) for 30 minutes at 50°C followed by 72˚C for 
10 min.  
PCR master mix, 15 µl/well, was added directly to the 5 µl RT volume. Final 
concentrations for the PCR were 400 nM forward and reverse primers (IDT, 
Coralville, IA), 100 nM fluorogenic probe (Integrated DNA Technologies, San Diego 
CA), 5 mM MgCl2, and 200 μM deoxynucleotides, PCR buffer, 150 nM SuperROX 
dye (Biosearch Technologies, Novato, CA) and 0.25 U JumpStart Taq polymerase 
per reaction (Invitrogen, Carlsbad, CA), final concentrations. RT master mixes and 
all RNA samples and DNA oligo standards were pipetted by a Tecan Genesis RSP 
100 robotic workstation (Tecan US, Research Triangle Park, NC); PCR master 
mixes were pipetted utilizing a Biomek 2000 robotic workstation (Beckman, 
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Fullerton, CA). Each assembled plate was then covered with optically clear film 
(Applied Biosystems, Foster City, CA) and run in a Roche 480 Light Cycler real-time 
instrument using the following cycling conditions: 95°C, 2 min; followed by 40 cycles 
of 95°C, 12 sec and 60°C, 30 sec. The resulting data were analyzed using 
LightCycler 480 software v 1.5.1.62) with FAM reporter. 
Synthetic, PAGE purified DNA oligos used as standards (sDNA) 
encompassed at least the entire 5’ – 3’ PCR amplicon for the assay (Sigma-
Genosys, The Woodlands, TX). Each oligo standard was diluted in 100 ng/µl E. coli 
tRNA-H2O (Roche Diagnostics, Indianapolis, IN) and spanned a 5-log range in 10-
fold decrements starting at 0.8 pg/reaction. It has been shown for several assays 
that in vitro transcribed RNA amplicon standards (sRNA) and sDNA standards have 
the same PCR efficiency when the reactions are performed as described above with 
PCR amplicons of less than 100 bases in length.  Data are expressed as relative 
expression normalized to 18S and to DMSO controls.  Each treatment group was 
repeated in triplicate. 
2.7 Cell Viability Assays 
 To evaluate the effect of inhibition of the Ras/MAPK pathway alone and in 
combination with the PI3K/AKT pathway on endometrial cancer cells with an 
activating KRas mutation in the presence and absence of estradiol, cell viability 
assays were performed.  Ishikawa endometrial cancer cells stably transfected with 
wild type KRas and mutant KRas were plated in 96 well plates at a density of 4x103 
cells/well in phenol free medium with charcoal stripped FBS.  Cells were incubated 
for 24 hours at 37°C under 5% CO2 prior to treatment.  Medium was then replaced 
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with 100uL of phenol free medium containing DMSO alone, 10nM trametinib, or 
10nM trametinib + 250nM BEZ235.  All treatment regimens were repeated without 
estradiol and plus 0.01uM estradiol.  Following treatment for 48 hours, cells were 
incubated for 3.5 hours with 20uL MTT (3-(5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) dye (Affymetrix, Santa Clara, CA) at 37°C under 5% 
CO2.  The reaction was then halted using 150uL of MTT solvent (2-propanol, 0.1% 
NP40, 4mM HCl) and plates were gently shaken for 15 minutes.  Absorbance at 
590nm and 630nm was then recorded and the change in optical density (ΔOD) was 
calculated.  Three independent assays were performed for all assays in triplicate. 
2.8 Reverse Phase Protein Array  
 To further validate our in vitro findings and to evaluate relevant pathways 
involved in ERα signaling, reverse phase protein array (RPPA) was performed with 
the aide of the Functional Proteomics RPPA Core at the University of Texas MD 
Anderson Cancer Center.  Ishikawa cells stably transfected with wild type KRas and 
mutant KRas (G12V) were plated in 6 well plates to 70% confluency at 37°C under 
5% CO2.  Cells were serum starved overnight for 12 hours in phenol free DMEM 
with L-glutamine containing DMSO alone or 10nM trametinib.  Cells were then 
stimulated with 0.01uM estradiol and whole cell lysates were harvested at 30 
minutes.   
Cells were washed twice with sterile PBS and 150uL of RPPA lysis buffer, 
containing 1%Triton X-100, 50mM HEPES, pH7.4, 150mM NaCl, 1.5mM MgCl2, 
1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, 
containing freshly added protease and phosphatase inhibitors, was added to plates.  
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Plates were incubated on leveled ice for 20 minutes with occasional shaking every 5 
minutes.  Cells were scraped off plates with a spatula and cell lysates were 
collected in 1.5mL microcentrifuge tubes.  Lysates were then centrifuged at 14,000 
rpm for 10 minutes at 4°C.  The supernatant was collected and protein 
concentration was determined using the PierceTM bicinchoninic acid (BCA) Protein 
Assay Kit per manufacturer protocol (Thermo Fisher Scientific, Waltham, MA). 
Protein concentration was adjusted to 1mg/mL and the cell lysate was mixed with 
4x SDS sample buffer (40% glycerol, 8% SDS, 0.25M Tris-HCL, pH6.8, 2-
mercaptoethanol at 1/10 the volume) without bromophenol blue at  a ratio of 3 parts 
cell lyate to 1 part 4x SDS sample buffer.  Samples were boiled for 5 minutes and 
stored at -80°C. 
 Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) 
and diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% 
SDS). Serial diluted lysates were arrayed on nitrocellulose-coated slides (Grace 
Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots were 
arranged on each slide including the spots corresponding to positive and negative 
controls prepared from mixed cell lysates or dilution buffer, respectively. 
Each slide was probed with a validated primary antibody plus a biotin-
conjugated secondary antibody. Only antibodies with a Pearson correlation 
coefficient between RPPA and western blotting of greater than 0.7 were used in 
reverse phase protein array study. Antibodies with a single or dominant band on 
western blotting were further assessed by direct comparison to RPPA using cell 
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lines with differential protein expression or modulated with ligands/inhibitors or 
siRNA for phospho- or structural proteins, respectively. 
The signal obtained was amplified using a Dako Cytomation–catalyzed 
system (Dako) and visualized by DAB colorimetric reaction. The slides were 
scanned, analyzed, and quantified using a customerized-software Microvigene 
(VigeneTech Inc.) to generate spot intensity. 
Each dilution curve was fitted with a logistic model (“Supercurve Fitting” 
developed by the Department of Bioinformatics and Computational Biology in MD 
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits 
a single curve using all the samples (i.e., dilution series) on a slide with the signal 
intensity as the response variable and the dilution steps are independent variable. 
The fitted curve is plotted with the signal intensities – both observed and fitted - on 
the y-axis and the log2-concentration of proteins on the x-axis for diagnostic 
purposes. The protein concentrations of each set of slides were then normalized by 
median polish, which was corrected across samples by the linear expression values 
using the median expression levels of all antibody experiments to calculate a 
loading correction factor for each sample. 
2.9 Statistical Analysis 
 Values are expressed as the mean ± standard error of the mean.  Data were 
analyzed with independent t-test for pairwise comparisons.  For multiple 
comparisons, analysis of variance (ANOVA) was used with multiple comparisons 
determined by the Tukey test.  Differences with p<0.05 are considered statistically 
significant. 
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 Results of the RPPA experiment were analyzed with the assistance of the 
Bioinformatics Core at the University of Texas MD Anderson Cancer Center.  For 
RPPA analysis, the data processing and statistical analyses were performed in R.  
Median-centered data were used and principal component analysis (PCA) was run 
to check the grouping of samples.  Feature-by-feature two-way ANOVA was used to 
compare protein expression profiles between different cell types and treatments.  
Beta-uniform mixture (BUM) models were utilized to fit the resulting p-value 
distributions in order to adjust for multiple comparisons.   
3. Results 
3.1 Effect of Treatment Regimen on Tumor Growth 
 Following intraperitoneal injection of tumor cells, mice were placed into 1 of 8 
treatment groups and treated daily by oral gavage.  Mice were treated until one 
mouse in any treatment group became moribund at which point all mice were 
euthanized and necropsy performed.  Time to moribund was 51 days for mice 
injected with Ishikawa cells and 31 days for mice injected with HEC1A cells.  
Overall, 84.9% and 97.3% of mice developed tumors in the Ishikawa group and 
HEC1A group respectively.   Mouse weight and serum ALT level were used as a 
marker of treatment toxicity.  There were no differences in mean mouse weight or 
mean serum ALT among any of the treatment regimens in either the Ishikawa or 
HEC1A group (Table 3).   
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In the Ishikawa group, mice treated with everolimus alone (p=0.006), 
everolimus and metformin (p=0.0013), everolimus and letrozole (0.0004), and all 
three drugs in combination (p=0.016) had significantly lower mean tumor weights 
when compared with control animals.  Animals treated with everolimus and letrozole 
had the lowest mean tumor weight compared to controls. In contrast, only mice 
treated with all three drugs in combination had significantly lower mean tumor 
weight compared to control treated animals in the HEC1A group(p=0.0076)(Figure 
6). 
Table 3.  Summary of xenograft results The time to moribund 
for mice in the Ishikawa group was 51 days and 85% of mice 
developed tumor.  The time to moribund for mice in the HEC1A 
group was 31 days and 97% of mice developed tumor.  There 
were no differences in mean mouse weight or mean serum ALT 
among any treatment regimens in either the Ishikawa or HEC1A 
group. 
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Interestingly, when mean tumor weight were normalized to controls, animals 
in the Ishikawa group had significantly better response to letrozole compared to the 
HEC1A group (Fold change:0.65 vs 1.23, p=0.035, Figure 7).  As a result, we 
sought to investigate the role of the Ras/MAPK pathway in estrogen signaling in 
tumors with and without an activating KRas mutation.  
 
 
Figure 6.  In vivo effect of metformin, everolimus, and 
letrozole on tumor weight in xenograft model  All treatment 
groups including everolimus resulted in significant reduction in 
tumor weight in mice injected with Ishikawa cells, with the 
greatest effect seen in animals treated with everolimus and 
letrozole.   Only the combination of all three drugs resulted in 
significant reduction in tumor weight in mice injected with HEC1A 
cells. 
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3.2 Effect of Treatment Regimen on Expression of pS6rp and Ki67 
 To evaluate downstream signaling through the PI3K/AKT pathway, orthotopic 
tumor tissues were stained for pS6rp using IHC.  In the Ishikawa group, tumors 
treated with everolimus (p=0.002) and everolimus and letrozole (p=0.0001) had 
significantly decreased levels of pS6rp.  In the HEC1A group, tumors treated with 
metformin (p=0.001) and all three drugs in combination (p=0.001) had significantly 
decreased levels of pS6rp compared to control treated tumors (Figure 8). 
Figure 7.  Tumors with an activating KRas mutation are 
resistant to treatment with letrozole.  Tumors in the HEC1A 
group were resistant to treatment with letrozole compared to 
tumors in the Ishikawa group.  Given the known molecular 
aberrations in these cell lines, we hypothesized that tumors with 
activating KRas mutations are resistant to endocrine therapy 
compared to tumors with wild-type KRas. 
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Expression of Ki67 by IHC was utilized as a marker of cellular proliferation.  
In the Ishikawa group, only tumors treated with everolimus and letrozole together 
had significantly decreased cellular proliferation compared to control treated tumors 
(p=0.043). In the HEC1A group, tumors treated with metformin alone (p<0.001), 
metformin and letrozole (p=0.016), everolimus and letrozole (p=0.035), and all three 
drugs in combination (p=0.001) had decreased Ki67 expression compared to 
controls (Figure 9).   
 
Figure 8.  IHC for downstream activation of the PI3K/AKT 
pathway Levels of pS6rp were significantly decreased in tumors 
treated with everolimus and everolimus plus letrozole in the 
Ishikawa group.  Conversely, levels of pS6rp were significantly 
decreased in tumors treated with metformin and all three drugs 
in combination in the HEC1A group. 
36 
 
 
 
 
 
 
 
3.3 Effects of Ras/MAPK pathway on ERα Signaling  
 Given the relative resistance of HEC1A tumors to treatment with letrozole, 
we evaluated ERα signaling in Ishikawa and HEC1A endometrial cancer cells.  
Cells were serum starved overnight in phenol free medium and were then 
stimulated with 0.01uM estradiol.  HEC1A cells expressed ERα, however, there was 
no phosphorylation at ser167 in response to estradiol stimulation, as shown in figure 
10.  Conversely, Ishikawa cells expressed ERα and had phosphorylation present at 
ser167 at 10 and 30 minutes respectively. 
 
Figure 9.  IHC for cellular proliferation Ki67 expression was 
significantly lower in tumors treated with everolimus and 
letrozole in combination in the Ishikawa group.  In the HEC1A 
group, tumors treated with metformin, metformin and letrozole, 
everolimus and letrozole and all three drugs in combination had 
significantly decreased Ki67 expression compared to controls. 
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Given the presence of ERα, but no phosphorylation at ser167 in response to 
estradiol in HEC1A cells, we utilized Ishikawa cells stably transfected with wild type 
KRas and mutant KRas (G12V) to further evaluate signaling through ERα.  Similar 
to HEC1A cells, Ishikawa cells transfected with mutant KRas expressed ERα, but 
had no phosphorylation at ser167.  Conversely, Ishikawa cells transfected with wild 
type KRas expressed ERα and had retained phosphorylation at ser167.  Similarly, 
cells with wild type KRas had increased phosphorylation at ser118 compared to 
cells with mutant KRas (Figure 11A). 
 To evaluate the role of the Ras/MAPK pathway in the differential 
phosphorylation seen at ser167, Ishikawa cells were then treated with 10nM 
trametinib, a MEK inhibitor, and western blot performed for signaling through ERα.  
Following treatment with trametinib, both Ishikawa cells with wild type KRas and 
mutant KRas had signaling through ERα shown by positive phosphorylation at 
ser167.  In addition, treatment with trametinib increased phosphorylation at ser118 
Figure 10.  Western blot following estradiol stimulation  
Ishikawa cells demonstrated positive ERα expression and 
phosphorylation of ERα at ser167.  Conversely, HEC1A cells 
expressed ERα, but exhibited no phosphorylation of ERα at 
ser167. 
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in mutant KRas cells, while little effect was seen in cells with wild type KRas (Figure 
11A).   
The addition of BEZ235, a pan-PI3K/mTOR inhibitor, decreased 
phosphorylation at ser167 in Ishikawa cells with wild type and mutant KRas.   
Similarly, treatment with BEZ236 decreased phosphorylation at ser118 in both wild 
type and mutant KRas cells, however a greater effect was seen in mutant KRas 
cells (Figure 11A).    
Immunoblot for total ERα showed that cells with mutant KRas had decreased 
total ERα expression compared to cells with wild type KRas (Figure 11A).  Figure 
11B shows a graphical depiction of relative densities for levels of phospho-ERα 
ser167, phospho-ERα ser118, and total ERα.   
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Figure 11.  Western blot for ERα signaling  A. Cells with 
mutant KRas express ERα but are not phosphorylated at ser167 
in response to estradiol stimulation.  Treatment with a MEK 
inhibitor restored signaling through ser167.  Addition of a pan-
PI3K/mTOR inhibitor resulted in decreased phosphorylation at 
ser167.  Cells with mutant KRas have decreased 
phosphorylation at ser118 and phosphorylation increased 
following treatment with a MEK inhibitor.  Addition of a pan-
PI3K/mTOR inhibitor decreased phosphorylation at ser118, with 
a greater effect seen in mutant KRas cells.  Lastly, cells with 
mutant KRas have decreased expression of total ERα compared 
to cells with wild type KRas. B. Graphical Depiction of 
immunoblot results expressed as relative density normalized to 
β-actin control at the 30 minute time point. 
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3.4 Role of PI3K/AKT and Ras/MAPK member kinases in ERα Signaling 
 Given that AKT, p70 S6 kinase, ERK1/2, and p90RSK are all able to 
phosphorylate ERα independent of estrogen, we evaluated phosphorylation at 
these nodes in the PI3K/AKT and Ras MAPK pathways to evaluate the differential 
signaling through ERα seen in wild type and mutant KRas Ishikawa cells. 
 There were no differences in AKT phosphorylation or p70 S6 kinase 
phosphorylation between wild type and mutant KRas cells.  In addition, treatment 
with trametinib resulted in minimal change in phosphorylation of either AKT or p70 
S6 kinase.  The addition of BEZ235 decreased phosphorylation of AKT and p70 S6 
kinase and in both wild type and mutant KRas cells (Figure 12A).  These changes 
are quantified in figure 12B and are expressed as relative density normalized to β-
actin controls. 
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Following stimulation with estradiol, Ishikawa cells with wild type KRas 
demonstrated increased phosphorylation of ERK1/2 compared to mutant KRas 
cells.  Following treatment with trametinib, phosphorylation at ERK1/2 was absent in 
wild type KRas cells but increased in mutant KRas cells.  The addition of BEZ235 
Figure 12.  Western blot for PI3K/AKT kinases involved in 
ERα signaling  A. No differences in levels of phospho AKT or 
phospho p70 S6 kinase were seen in response to estradiol 
stimulation.  Both had minimal decrease in expression following 
treatment with trametinib.  The addition of BEZ235 to trametinib 
resulted in decreased phosphorylation both kinases.  B. 
Graphical depiction of immunoblot results expressed as relative 
density normalized to β-actin control at the 30 minute time point. 
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resulted in a relative decrease in phosphorylation of ERK1/2 in both wild type and 
mutant KRas cells (Figure 13C shows a positive control).   
 Ishikawa cells with wild type KRas demonstrated increased phosphorylation 
of p90RSK compared to mutant KRas cells following estradiol stimulation.  
Treatment of cells with trametinib led to a relative decrease in phosphorylation of 
p90RSK in wild type cells and increased phosphorylation p90RSK in KRas mutant 
cells.  The addition of BEZ235 lead to decreased phosphorylation of p90RSK in 
both wild type and mutant KRas Ishikawa cells (Figure13A).  This is depicted 
graphically in figure 13B. 
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3.5 Quantitative RT-PCR for Estrogen-Induced Genes 
To evaluate the functional consequence of differential estrogen signaling in 
wild type and mutant KRas endometrial cancer cells, qRT-PCR was performed for 7 
estrogen induced genes: EIG121, sFRP1, IGF1, PR, HOXA10, ERα, and RALDH2.  
Figure 13.  Western blot for Ras/MAPK kinases involved in 
ERα signaling  A. Wild type KRas cells had increased 
phosphorylation of ERK1/2 and p90RSK in response to estradiol 
stimulation compared to mutant KRas cells.  Following treatment 
with trametinib, wild type cells exhibited decreased 
phosphorylation at ERK1/2 and p90RSK, while KRas mutant 
cells had increased phosphorylation of ERK1/2 and p90RSK.  
The addition of BEZ235 to trametinib resulted in decreased 
phosphorylation of both kinases in wild type and KRAS mutant 
cells.  B. Graphical Depiction of immunoblot results expressed 
as relative density normalized to β-actin control at the 30 minute 
time point. C. Western blot for phosphorylated ERK1/2 and 
p90RSK expression following treatment with trametinib and 
BEZ235 with positive control. 
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Cells were treated with DMSO alone, trametinib, or trametinib and BEZ235 and 
stimulated with estradiol for 16 hours.   
sFRP1 (p=0.002) and RALDH2 (p=0.007) had significantly lower expression 
in mutant KRas cells.  IGF1, PR, HOXA10, and PR also showed a trend toward 
decreased expression (Figure 14).   
 
 
 
 
 
 
Figure 14.  Quantitative RT-PCR for estrogen-induced genes 
following estradiol stimulation  sFRP1 and RALDH2 had 
decreased expression in mutant KRas cells following estradiol 
stimulation.  All experiments were performed in triplicate. 
45 
 
 
All 7 genes showed a trend towards increased relative expression in mutant 
KRas cells following treatment with trametinib.  In contrast, relative expression was 
either decreased or unchanged when cells with wild type KRas were treated with 
trametinib.  Four of the genes, EIG121 (p=0.001), sFRP1 (p<0.0001), PR 
(p=0.0003), and HOXA10 (p=0.002) had significantly increased relative expression 
in KRas mutant Ishikawa cells following treatment with trametinib compared with 
wild type cells (Figure 15). 
The addition of BEZ235 to trametinib resulted in significantly decreased 
expression of EIG121 (p<0.0001), sFRP1 (p<0.0001), IGF1 (p=0.003), PR 
(p<0.0001), HOXA10 (p<0.0001), and RALDH2 (p=0.035) in mutant KRas cells and 
EIG121 (p=0.0003), sFRP1 (p=0.0003), PR (p=0.006), and HOXA10 (p=0.008) in 
wild type cells (Figure 15).  
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Figure 15.  Quantitative RT-PCR for estrogen–
induced genes  Ishikawa cells expressing mutant 
KRas had increased expression of estrogen-
induced genes following treatment with a MEK 
inhibitor, while cells with wild type KRas had stable 
or decreased expression.  Both mutant and wild 
type cells had decreased expression of estrogen-
induced genes when a pan-PI3K/mTOR inhibitor 
was added to the treatment regimen.  All 
experiments were performed in triplicate. 
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3.6 Cell Viability Studies 
 To evaluate the effect of differential signaling on tumor growth, cell viability 
assays were performed with wild type and mutant KRas Ishikawa cells.   Cells were 
treated with DMSO alone, 10nM trametinib, and 10nM trametinib with 250nM 
BEZ235 for 48 hours in the presence and absence of estradiol.   Ishikawa cells with 
mutant KRas had significantly higher cell viability at 48 hours compared to cells with 
wild type KRas at baseline (p=0.0012). 
 Treatment with trametinib alone did not decrease relative cell viability in the 
presence of estradiol in cells with either wild type or mutant KRas.  In Ishikawa cells 
with wild type KRas, there was a significant reduction in relative cell viability 
compared to DMSO treated controls in cells treated with trametinib in the absence 
of estradiol compared to those treated in the presence of estradiol (p=0.001).  This 
significant reduction was also seen in Ishikawa cell with mutant KRas, where cells 
treated with trametinib in the absence of estradiol had decreased viability 
(p=0.0008).  In addition, cells treated with the combination of trametinib and 
BEZ235 in the presence of estrogen had significantly decreased viability when 
compared to cells treated with trametinib alone in both the wild type (p=0.0001) and 
mutant KRas groups (p<0.0001, Figure 16). 
 There was no difference in relative cell viability in mutant KRas cells treated 
with trametinib alone or trametinib and BEZ235 in the absence of estrogen.  
Conversely, in wild type KRas cells, the combination of trametinib and BEZ235 
resulted in significantly reduced cell viability compared to trametinib alone 
(p=0.0003, Figure 16.) 
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Figure 16.  Cell viability assays in Ishikawa cells with wild 
type and mutant KRas  Treatment with trametinib alone had no 
effect on cell viability in either wild type or mutant KRas cells in 
the presence of estradiol.  However, both wild type and mutant 
KRas cells had decreased cell viability after treatment with 
trametinib in the absence of estradiol compared to cells treated 
in the presence of estradiol.  Both wild type and mutant KRas 
cells had decreased relative cell viability when treated with 
trametinib and BEZ235 in the presence of estradiol compared to 
trametinib alone in the presence of estradiol.  Ishikawa cells with 
wild type KRas had significantly decreased relative cell viability 
when treated with trametinib and BEZ235 together compared to 
trametinib alone in the absence of estrogen.  There was no 
difference in relative cell viability seen in mutant KRas cells 
treated with trametinib alone or trametinib plus BEZ235 in the 
absence of estrogen. 
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3.7 RPPA Analysis 
 RPPA analysis was performed to validate our in vitro findings of differential 
ERα signaling and to investigate alternate pathways that may contribute to this 
differential signaling.  Ishikawa cells with wild type KRas and mutant KRas were 
treated with DMSO control and 10nM trametinib.  They were then stimulated with 
estradiol and whole cell lysates collected at 30 minutes.  These lysates were 
analyzed using the RPPA platform.  Analyses of protein expression were performed 
based on cell type, defined as the presence of wild type or mutant KRas, treatment 
type, defined as DMSO control or trametinib, or the interaction of cell type and 
treatment type.  Principal component analysis revealed grouping of samples by 
KRas status and treatment group (control or 10nM trametinib, Figure 17).   
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After adjusting for multiple comparisons, 38, 44, and 70 proteins were 
differentially expressed between Ishikawa cells with wild type and mutant KRas at 
false discovery rate levels of 0.01, 0.02, and 0.05 respectively.  Overall, Ishikawa 
cells with mutant KRas had increased phosphorylation of proteins involved in the 
Ras/MAPK pathway including EGFR (1.46 fold, p<0.001), ERBB2 (1.37 fold, 
p<0.0001), MAPK14 (1.42 fold, p=0.001), SHC (1.21 fold, p=0.002), and MAPK8 
Figure 17.  Principal component analysis of normalized 
RPPA data The first principal component (vertical line) splits the 
samples by treatment status.  The second principal component 
(horizontal line) splits samples by cell line involved. 
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(1.25 fold, p=0.004) (Figure 18A, C).  Furthermore, consistent with the previous in 
vitro studies, Ishikawa cells harboring a KRas mutation had decreased expression 
of ERα (ESR1, p=0.0001).  KRas mutant cells also had decreased expression of the 
androgen receptor (AR, p<0.0001) and the progesterone receptor (PGR, p<0.0001) 
(Figure 18B). 
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Figure 18.  RPPA analysis of 
samples by KRas mutation status  
A. A total of 44 proteins were 
associated with cell type at a false 
discovery rate of 0.02.  Pearson 
correlation was used to compute 
distance and Ward’s linkage was 
used as the clustering method.  B. 
Androgen receptor, progesterone 
receptor, and ERα all had 
decreased expression in Kras 
mutant Ishikawa cells compared to 
cells with wild type KRas.  C. 
Mutant KRas cells had increased 
phosphorylation of members of the 
Ras/MAPK pathway. 
53 
 
 
In addition, differences in protein expression profiles were seen in 17, 33, 
and 54 proteins due to treatment regimen at false discovery levels of 0.01, 0.02, 
and 0.05 (Figure 19).  Consistent with MEK inhibition, there was a 6.5 fold decrease 
in MAPK1/MAPK3 expression (p<0.0001) in cells treated with a MEK inhibitor.   
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We then evaluated the interaction between cell type and treatment type.  
While there was clustering of groups based on this interaction with significant 
differences in expression, there were no specific pathways that as a whole were up 
or down regulated by MEK inhibition based on KRas mutational status (Figure 20).     
Figure 19.  RPPA analysis by treatment group  A. A total of 
54 proteins were associated with treatment type at a false 
discovery rate of 0.05.  Pearson correlation was used to 
compute distance and Ward’s linkage was used as the clustering 
method.  B. Cells treated with trametinib had a 6.5 fold decrease 
in MAPK1/MAPK3 expression.  Conversely, phosphorylation of 
p70 S6 kinase and s6 ribosomal protein increased following 
treatment with trametinib. 
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Figure 20.  RPPA analysis by the interaction of cell type and 
treatment type  A total of 47 proteins were associated with the 
interaction of cell type and treatment type at a false discovery 
rate of 0.1.  Pearson correlation was used to compute distance 
and Ward’s linkage was used as the clustering method. 
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4. Discussion 
Hormonal therapy remains a first line option for the treatment of recurrent 
endometrial cancer.  Patients with low grade, hormone receptor positive disease are 
felt to be optimal candidates for these therapies, however, not all patients respond, 
with response rates ranging from 10-30% with various regimens(91-94).  Given this 
variability in response, a better understanding of the crosstalk with pathways 
involved in estrogen signaling, including the PI3K/AKT and Ras/MAPK pathway, is 
needed to help predict response to endocrine therapies.  There is extensive 
literature supporting the role of ligand independent activation of ERα by member 
kinases of both the PI3K/AKT and Ras/MAPK pathways(44).  In addition, 
combination therapies targeting the estrogen receptor pathway and the PI3K/AKT 
pathway have been evaluated in numerous cancers, including recurrent endometrial 
cancer(98, 104).  However, no studies to date have evaluated the role of the 
Ras/MAPK pathway, and KRas mutation status specifically, in predicting response 
to hormonal therapy in endometrial cancer.  Our in vivo model demonstrated that 
tumors with an activating KRas mutation are resistant to hormonal therapy, even in 
combination with an mTOR inhibitor.  Tumors responded only following the addition 
of metformin, which has previously been shown to have activity in KRas mutant 
endometrial cancer cells(92).   
Other studies in breast cancer have similarly found that activation of the 
Ras/MAPK pathway is associated with resistance to hormonal therapy(107-109).  
Guitierrez et al. showed that increased expression of phosphorylated ERK, but not 
phosphorylated AKT was associated with resistance to tamoxifen therapy(109).  
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However, these studies have mainly been correlative and have not focused on 
cancers with KRas mutations specifically.   
Given the differential response to endocrine therapy in our in vivo model, we 
investigated ERα signaling, downstream expression of estrogen-induced genes, 
protein expression, and cell viability in vitro to further dissect the role of the 
Ras/MAPK pathway in relation to the estrogen receptor pathway in endometrial 
cancer.  First, we demonstrated that KRas mutant cells have decreased expression 
of ERα compared to cells with wild type KRas.  This decrease in expression was 
mirrored in functional proteomic analysis.    In addition, KRas mutant cells had no 
detectable phosphorylation at ser167 and decreased phosphorylation at ser118 in 
response to estradiol stimulation.  These findings suggest that KRas mutant cells 
are functionally ER negative, and may be unresponsive to estrogen even when the 
estrogen receptor is expressed.   Furthermore, Ishikawa cells with wild type KRas 
actually demonstrated increased phosphorylation of ERK1/2 in response to estradiol 
stimulation compared to mutant KRas cells.  Taken in concert, the decreased 
phosphorylation of ERK1/2 and decreased phosphorylation at ser167 and ser118 
suggest that mutant KRas cells are resistant to nongenomic activation of the 
Ras/MAPK pathway by estradiol compared to wild type cells.  This hypothesis shifts 
the paradigm of estrogen induced tumorigenesis in endometrial cancer.   While 
ligand dependent ERα activation certainly plays a role in downstream transcriptional 
activation of genes including growth factors, nongenomic activation of the PI3K/AKT 
and Ras/MAPK pathway may also be a highly relevant event leading to proliferation 
in endometrial cancer.  Given that KRas mutant cells may not be as susceptible to 
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nongenomic activation, hormonal therapy will not be as effective in the treatment of 
these tumors. 
In our in vitro studies, KRas mutant cells had decreased activation of ERα.  
As a result, we sought to investigate if inhibition of the Ras/MAPK pathway could 
restore phosphorylation at relevant serine residues.  Interestingly, treatment with a 
MEK inhibitor restored signaling at ser167, increased signaling at ser118 and lead 
to increased expression of downstream estrogen-induced genes.   This in turn 
suggests that KRas mutant endometrial cancer cells treated with a MEK inhibitor 
may have enhanced nongenomic activation of the Ras/MAPK pathway in response 
to estradiol stimulation. 
Hou et al. investigated the use of MEK inhibition in ER positive ovarian 
cancers and found an increase in ERα expression following treatment with a MEK 
inhibitor.  Similar to our study, they found increased expression of ERα and 
downstream estrogen-induced genes following treatment with a MEK inhibitor that 
was not associated with increased signaling through AKT(109).  However, there are 
important differences that need to be explored when drawing comparisons with the 
current study. The study performed by Hou et al. found an increase in expression of 
phosphorylation at ser118, but not ser167 following treatment with a MEK inhibitor.  
This is in contrast to the present study, where we demonstrated that treatment with 
a MEK inhibitor resulted in increased phosphorylation at both ser167 and ser118.  
These discordant findings could be the result of multiple methodological differences.  
First, we utilized Ishikawa endometrial cancer cells with and without an activating 
KRas mutation, while Hou et al based their studies on ERα expression alone in 
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SKOV3 ovarian cancer cells.  Second, we evaluated phosphorylation at ser167 and 
ser118 at time points ranging from 10 minutes to 4 hours, the rapid time frame in 
which nongenomic estrogen signaling occurs, while Hou et al. evaluated 
phosphorylation at 24 hours.  Despite these differences, this study also showed that 
combination treatment with a MEK inhibitor and an anti-estrogen decreased cell 
viability.   
In order to investigate the differential estrogen signaling seen in cells with 
and without an activating KRas mutation, we evaluated activity of 4 of the 
downstream kinases in the PI3K/AKT and Ras/MAPK pathways known to 
phosphorylate ERα in a ligand independent fashion.  There were no differences in 
phosphorylation at AKT or p70 S6 kinase, both members of the PI3K/AKT pathway.  
This suggests that restoration of phosphorylation at ser167 and ser118 are not the 
result of upregulation of the PI3K/AKT pathway following treatment with a MEK 
inhibitor.  However, there were differences in phosphorylation of ERK1/2 and p90 
RSK, members of the Ras/MAPK pathway.  Cells with wild type KRas had 
decreased phosphorylation of ERK1/2 and p90RSK in response to treatment with a 
MEK inhibitor, while cells expressing mutant KRas had increased phosphorylation 
of ERK1/2 and p90RSK in response to treatment with a MEK inhibitor.  These 
findings support the hypothesis that treatment of KRas cells with MEK inhibition 
leads to resensitization and nongenomic activation of the Ras/MAPK pathway in 
response to estradiol stimulation.   
 Our findings could have important implications for the treatment of 
endometrial cancer, where as many as 30% of cancers harbor activating KRas 
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mutations.  It is clear that single agent therapy, with hormonal therapy or MEK 
inhibition, is not effective in the treatment of recurrent disease.  As a result rational 
combinations of targeted therapeutics are needed to improve survival in this patient 
population.  Given the extensive crosstalk between the ERα, PI3K/AKT, and 
Ras/MAPK pathways, it seems prudent to address all three when approaching the 
design of clinical trials.  Current trials include the combination of MEK inhibitors and 
inhibitors of the PI3K/AKT pathway.  These inhibitors in combination should 
decrease downstream activation of growth signals associated with their own 
pathways, but should also decrease downstream activation of estrogen-induced 
growth signals by decreasing ligand independent activation of ERα.  While this 
combination addresses all three relevant pathways, these regimens have already 
shown significant toxicity in this group of patients in phase I and II clinical trials.  
Indeed, the safety lead in group for a phase II trial at our institution combining a 
MEK inhibitor and AKT inhibitor has recently been suspended due to significant 
toxicities including rash, diarrhea with electrolyte abnormalities, hypertension, and a 
possible cerebrovascular accident(110).  This further highlights the needs for 
combination therapies with improved side effect profiles.   
To evaluate possible combinations of targeted therapeutics, we evaluated 
cell viability in vitro in cells with and without KRas mutation.  Treatment of KRas 
mutant cells with a MEK inhibitor in the presence of estrogen did not decrease cell 
viability, while treatment with a MEK inhibitor in the absence of estrogen 
significantly decreased cell viability.  Interestingly, the addition of a pan-PI3K/mTOR 
inhibitor did not decrease cell viability further when added to the MEK inhibitor in the 
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absence of estrogen in KRas mutant cells.   Conversely, the addition of PI3K 
inhibition to MEK inhibition did significantly decrease cell viability in endometrial 
cancer cells with wild type KRas. While the addition of BEZ235 significantly 
decreased cell viability when added to trametinib in the absence of estradiol in wild 
type cells, the actual difference in relative change was small.  This raises the 
question of whether the addition of a PI3K/mTOR inhibitor would have clinically 
meaningful results in practice.   
Given these findings, three possible future trial designs could be proposed. 
The possible design is a single arm trial of a MEK inhibitor in combination with an 
anti-hormonal therapy for patients with ER positive recurrent endometrial cancer 
and an activating KRas mutation (Figure 21A).   The combination of a MEK inhibitor 
with a hormonal agent could offer similar efficacy with an improvement in side effect 
profile over combination therapies currently in phase II clinical trials.    This 
combination has also been suggested by other authors in the treatment of ER 
positive ovarian cancer(57).  A second design would again start with a single arm 
trial consisting of a MEK inhibitor in combination with an anti-hormonal therapy, but 
patients would then be randomized following 8-12 weeks of therapy if they had 
stable disease to continue therapy with a MEK inhibitor and anti-hormonal or to add 
a PI3K/mTOR inhibitor to a MEK inhibitor in place of the anti-hormonal therapy.  
Patients with an objective response at 8-12 weeks would continue with a MEK 
inhibitor and anti-hormonal and patients with progressive disease would then be 
switched to a MEK inhibitor in combination with a PI3K/mTOR inhibitor (Figure 
21B).  A third, more comprehensive design, would include all patients with ER 
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positive recurrent disease and would address the question raised by our in vitro cell 
viability studies of whether the addition of a PI3K/mTOR inhibitor would add 
clinically meaningful benefit for patients with wild type KRas. This design would 
stratify patients by KRas mutation status and patients would be randomized to 
receive a MEK inhibitor plus an anti-hormonal therapy or a MEK inhibitor in 
combination with a PI3K/mTOR inhibitor (Figure 21C).   
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Figure 21.  Possible future clinical trial designs 
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One limitation of our study is that we used Ishikawa cells to transfect wild 
type and mutant KRas for our in vitro models, as Ishikawa cells exhibit loss of PTEN 
expression at baseline.  Indeed, activation of the PI3K/AKT pathway itself has been 
shown to be a predictive marker for nonresponse to MEK inhibition in KRas mutant 
cancers(89).  However, even in the presence of baseline loss of PTEN expression, 
cells transfected with mutant KRas had decreased cell viability when treated with 
trametinib in the absence of estradiol, and the addition of BEZ235 did not increase 
response.  In addition, as both the wild type and mutant KRas cells exhibited loss of 
PTEN expression, this molecular aberration was controlled for in our in vitro model.  
Lastly, activation of the PI3K/AKT and Ras/MAPK pathways co-occurs in a 
proportion of endometrial tumors and allows these preclinical findings to be applied 
to a broader group of endometrial tumors(6, 7, 37, 106, 107).  
By stimulating cells with estradiol and assessing signaling at rapid time 
points, we essentially evaluated nongenomic activation of the PI3K/AKT and 
Ras/MAPK pathways and the resultant effect on ligand independent 
phosphorylation at ERα.  This leaves us with the inability to dissect out the 
individual roles of each type of signaling.  However, this does present a more 
complete model for estrogen signaling in aggregate and allows for accurate 
assessment of the sensitivity of these tumors to treatment with various therapeutic 
combinations.  This is ultimately what is important in designing future clinical trials 
using these agents. 
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5. Conclusions 
 In conclusion, endometrial cancer cells harboring KRas mutations are 
functionally ER negative in response to estradiol stimulation, despite expressing 
ERα, and are resistant to treatment with letrozole compared to cells with wild type 
KRas in vivo.  Treatment with a MEK inhibitor in vitro restores phosphorylation of 
ser167 and ser118 and in turn leads to increased expression of estrogen-induced 
genes.  Treatment of KRas mutant cells with MEK inhibition in the absence of 
estradiol leads to significantly reduced cell viability and the addition of PI3K 
inhibition does not increase response.  The addition of an anti-hormonal therapy to 
MEK inhibition may provide added benefit for patients with recurrent endometrial 
cancer compared to either therapy alone, with an improved side effect profile.  
These findings provide preclinical support for the combination of endocrine therapy 
and MEK inhibition in the treatment of KRas mutant endometrial tumors. 
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